The regenerative potential of Pax3/Pax7 on skeletal muscle injury.
Athlete
Cell proliferation Injuries.
Pax3 and Pax7
Pax3/Pax7
Skeletal muscle
Stem cells
Journal
Journal, genetic engineering & biotechnology
ISSN: 2090-5920
Titre abrégé: J Genet Eng Biotechnol
Pays: Netherlands
ID NLM: 101317150
Informations de publication
Date de publication:
17 Oct 2022
17 Oct 2022
Historique:
received:
16
03
2022
accepted:
08
10
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Skeletal muscle mishaps are the most well-known incidents in society, especially among athletes and the military population. From the various urgency, this accident needs to be cured more quickly. However, the current treatment still has some shortcomings and is less effective. In this case, Paired box 3 and Paired box 7 (Pax3/Pax7) proteins that induce stem cells could potentially be an alternative treatment for skeletal muscle injuries. This paper aimed to analyse the potential treatment of Pax3/Pax7 proteins inducing the stem cell for skeletal muscle injuries. We did a narrative review by gathering several scientific journals from several leading platforms like PubMed and Scopus. As common accidents, skeletal muscle disease could be due to workplace and non-workplace causes. The highest risk occurs in the athlete and military environment. The treatment of current skeletal muscle injuries is protection, rest, ice, compression, and elevation (PRICE), non-steroidal anti-inflammatory drugs (NSAIDs), and mechanical stimulation. However, it is considered less effective, especially in NSAIDs, inhibiting myogenic cell proliferation. The current finding indicates that the stem cells have markers known as Pax3/Pax7. The role of both markers in muscle injury, Pax3/Pax7, as transcription factors will induce cell division by H3K4 methylation mechanisms and chromatin modifications that stimulate gene activation. Regulation by Pax3/Pax7 factors that affect stem cells and stem cell proliferation is one of the alternative treatments. This regulation can accelerate the healing of injury victims, especially injuries to the skeletal muscles. Finally, after being compared, Pax3/Pax7 induces stem cells to have the potential to be one of the skeletal muscle injury treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Skeletal muscle mishaps are the most well-known incidents in society, especially among athletes and the military population. From the various urgency, this accident needs to be cured more quickly. However, the current treatment still has some shortcomings and is less effective. In this case, Paired box 3 and Paired box 7 (Pax3/Pax7) proteins that induce stem cells could potentially be an alternative treatment for skeletal muscle injuries. This paper aimed to analyse the potential treatment of Pax3/Pax7 proteins inducing the stem cell for skeletal muscle injuries. We did a narrative review by gathering several scientific journals from several leading platforms like PubMed and Scopus. As common accidents, skeletal muscle disease could be due to workplace and non-workplace causes. The highest risk occurs in the athlete and military environment. The treatment of current skeletal muscle injuries is protection, rest, ice, compression, and elevation (PRICE), non-steroidal anti-inflammatory drugs (NSAIDs), and mechanical stimulation. However, it is considered less effective, especially in NSAIDs, inhibiting myogenic cell proliferation. The current finding indicates that the stem cells have markers known as Pax3/Pax7. The role of both markers in muscle injury, Pax3/Pax7, as transcription factors will induce cell division by H3K4 methylation mechanisms and chromatin modifications that stimulate gene activation.
CONCLUSION
CONCLUSIONS
Regulation by Pax3/Pax7 factors that affect stem cells and stem cell proliferation is one of the alternative treatments. This regulation can accelerate the healing of injury victims, especially injuries to the skeletal muscles. Finally, after being compared, Pax3/Pax7 induces stem cells to have the potential to be one of the skeletal muscle injury treatments.
Identifiants
pubmed: 36251225
doi: 10.1186/s43141-022-00429-x
pii: 10.1186/s43141-022-00429-x
pmc: PMC9574840
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
143Informations de copyright
© 2022. The Author(s).
Références
Nat Cell Biol. 2008 Jan;10(1):77-84
pubmed: 18066051
Sci Rep. 2019 Feb 6;9(1):1457
pubmed: 30728420
PLoS One. 2009;4(2):e4475
pubmed: 19221588
Respiration. 2013;85(1):3-10
pubmed: 23257690
NPJ Regen Med. 2020 May 11;5:10
pubmed: 32411395
Cell Death Differ. 2016 Jun;23(6):927-37
pubmed: 26868912
Infect Immun. 2019 Jul 23;87(8):
pubmed: 31138614
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):501-516
pubmed: 30843380
Ann Biomed Eng. 2014 Jul;42(7):1391-405
pubmed: 24366526
Physiol Rev. 2013 Jan;93(1):23-67
pubmed: 23303905
Am J Sports Med. 2005 May;33(5):745-64
pubmed: 15851777
Cell Death Dis. 2019 Jul 18;10(8):552
pubmed: 31320610
Front Pharmacol. 2015 Apr 21;6:87
pubmed: 25954202
Stem Cell Res Ther. 2022 Feb 5;13(1):56
pubmed: 35123554
Cell Mol Life Sci. 2019 Jul;76(13):2559-2570
pubmed: 30976839
Semin Cell Dev Biol. 2015 Aug;44:115-25
pubmed: 26424495
Genes Dev. 2005 Jun 15;19(12):1426-31
pubmed: 15964993
Dev Cell. 2012 Jun 12;22(6):1208-20
pubmed: 22609161
Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1534-9
pubmed: 26811474
Biochem Biophys Res Commun. 2013 May 3;434(2):316-21
pubmed: 23541574
Stem Cell Res Ther. 2018 Jul 17;9(1):195
pubmed: 30016973
Sci Transl Med. 2011 Feb 2;3(68):68ra9
pubmed: 21289273
Front Nutr. 2022 Feb 10;9:825629
pubmed: 35223956
J Exp Orthop. 2016 Dec;3(1):15
pubmed: 27447481
Stem Cell Res Ther. 2020 Jun 17;11(1):238
pubmed: 32552916
Acta Myol. 2020 Dec 01;39(4):307-312
pubmed: 33458586
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13383-7
pubmed: 19666532
Dev Cell. 2015 Apr 6;33(1):56-66
pubmed: 25800090
Aviat Space Environ Med. 2012 Nov;83(11):1060-6
pubmed: 23156094
ISRN Orthop. 2012 Apr 26;2012:689012
pubmed: 24977084
Sports Med Open. 2016;2:22
pubmed: 27213134
Mil Med. 2016 Sep;181(9):1075-80
pubmed: 27612356
J Cell Biol. 2006 Jan 2;172(1):103-13
pubmed: 16391000
Int J Mol Sci. 2021 Apr 05;22(7):
pubmed: 33916485
Stem Cells Int. 2012;2012:282348
pubmed: 22220178
Rev Bras Ortop. 2015 Dec 08;46(3):247-55
pubmed: 27047816
Brain Behav Immun. 2006 Sep;20(5):423-9
pubmed: 16647245
Science. 1999 Apr 16;284(5413):489-93
pubmed: 10205057
C R Biol. 2007 Jun-Jul;330(6-7):530-3
pubmed: 17631448
Int J Environ Res Public Health. 2021 May 20;18(10):
pubmed: 34065250
Open Biol. 2020 Sep;10(9):200223
pubmed: 32993416
J Cell Biol. 2006 Jan 2;172(1):91-102
pubmed: 16380438
Cell Stem Cell. 2012 Aug 3;11(2):231-41
pubmed: 22862948
PLoS One. 2017 Apr 25;12(4):e0176190
pubmed: 28441415
J Clin Invest. 2020 Mar 2;130(3):1466-1478
pubmed: 31794434
FEBS J. 2015 May;282(9):1571-88
pubmed: 25251895
Front Physiol. 2021 Jun 23;12:684899
pubmed: 34248671
Mil Med. 2020 Sep 18;185(9-10):e1461-e1471
pubmed: 32175566
Stem Cell Reports. 2019 Aug 13;13(2):352-365
pubmed: 31353225
J Virol. 2021 Oct 27;95(22):e0090421
pubmed: 34468171